Background: Gastric adenocarcinoma is known to be a markedly invasive disease with high potential for metastasis. Hepatocyte growth factor (HGF)/HGF receptor (MET) signaling pathway activation is an assumed mechanism of malignant transformation and metastatic potential of tumors. Metastasis associated with colon cancer-1 (MACC-1) has been identified as a key regulator of HGF/MET signaling. However, its role in gastric cancer is not well understood. Aim of this study is to assess the expression of MACC-1 in gastric cancer, its relation to other clinical and pathologic parameters and its impact on progression free and overall survival. Patient and Methods: Evaluation of MACC-1 protein expression by immune-histochemistry was done on paraffin-embedded tissues obtained from 46 patients with gastric cancer, where samples were taken from the tumor and adjacent normal mucosa. Results: MACC-1 was predominantly localized in the cytoplasm or membrane of the primary cancer cells. High MACC-1 expression was found in 63.1% (29/46) of tumor samples, while MACC-1 expression was not detected in normal mucosa (P 0.01). Expression of MACC-1 was significantly associated with older age, larger tumor size, deeper tumor invasion, presence of lymph node metastasis, distant metastasis and advanced clinical stage (p 0.05), while no relation was found with gender, tumor location or histologic classification (p > 0.05). Progression free and overall survival were significantly higher in patients with low MACC-1 expression compared to patients with high expression (Log Rank test, p = 0.02 and 0.04, consequently). Conclusion: Our study found that MACC-1 expression is strongly related to gastric cancer stage and both progression free and overall survival, suggesting that MACC-1 promotes tumorigenesis and its expression may
展开▼
机译：NEW RECOMMENDATIONS FOR THE QUALITY AND SAFETY OF TISSUES AND CELLS FOR CLINICAL APPLICATION AND ITS SIGNIFICANCE FOR THE PRACTICE OF TISSUE ESTABLISHMENTS PERFORMING CRYOPRESERVATION
机译：Efficacy of pre-operative chemotherapy with docetaxel, cisplatin, and s-1 (DCs therapy) and curative resection for gastric cancer with pathologically positive para-aortic lymph nodes
